ArticleScience translational medicine2024
Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays.
Abstract readComparative Study
In one paragraph
Article in Science translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Reconciliation of titer differences between SARS-CoV-2 neutralizing antibody assays.Journal of virology · 2026Article
- SARS-CoV-2 Omicron infection reveals imprinted antibody responses in the absence of vaccination.iScience · 2026Article
- Intranasal booster drives class switching and homing of memory B cells for mucosal IgA response.JCI insight · 2026Article
- Article
- Nonhuman primate antigenic cartography of SARS-CoV-2.Cell reports · 2025Article
- Development and Concordance of Binding and Neutralizing Assays to Determine SARS-CoV-2 Antibody Activity in Human Milk.Pathogens & immunity · 2025Article
- Article
- Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.Journal of virology · 2024Article
- Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera.NPJ vaccines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors.
Barbara MühlemannInstitute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.ORCID 0000-0002-5314-8530
Samuel H WilksCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.ORCID 0000-0002-7760-8474
Lauren BaraccoCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Meriem BeklizDepartment of Medicine, Faculty of Medicine, University of Geneva, CH-1211 Geneva, Switzerland.
Juan Manuel CarreñoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-9039-9275
Victor M CormanInstitute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.ORCID 0000-0002-3605-0136
Meredith E Davis-GardnerDepartment of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30329, USA.ORCID 0000-0002-6133-3613
Wanwisa DejnirattisaiWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.ORCID 0000-0001-7996-2699
Michael S DiamondDepartments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0002-8791-3165
Daniel C DouekVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Christian DrostenInstitute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.ORCID 0000-0001-7923-0519
Isabella EckerleDepartment of Medicine, Faculty of Medicine, University of Geneva, CH-1211 Geneva, Switzerland.ORCID 0000-0002-4850-7172
Venkata-Viswanadh EdaraDepartment of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30329, USA.ORCID 0000-0001-9321-7839
Madison EllisDepartment of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30329, USA.ORCID 0000-0002-0325-5477
Ron A M FouchierViroscience Department, Erasmus Medical Center, 3015 Rotterdam, Netherlands.ORCID 0000-0001-8095-2869
Matthew FriemanCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0003-0107-0775
Sucheta GodboleVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-7564-1748
Bart HaagmansViroscience Department, Erasmus Medical Center, 3015 Rotterdam, Netherlands.ORCID 0000-0001-6221-2015
Peter J HalfmannInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA.ORCID 0000-0002-1648-1625
Amy R HenryVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Terry C JonesInstitute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.ORCID 0000-0003-1120-9531
Leah C KatzelnickViral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-1033-6758
Yoshihiro KawaokaInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA.ORCID 0000-0001-5061-8296
Janine KimpelInstitute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Peter-Mayr-Str. 4b, 6020 Innsbruck, Austria.ORCID 0000-0002-5210-7905
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0003-4121-776X
Lilin LaiDepartment of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
Chang LiuWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.
Sabrina LusvarghiDivision of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20903, USA.ORCID 0000-0003-1793-0450
Benjamin MeyerCentre of Vaccinology, Department of Pathology and Immunology, University of Geneva, CH-1211 Geneva, Switzerland.ORCID 0000-0003-0601-3550
Juthathip MongkolsapayaWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.
David C MontefioriDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-0856-6319
Anna MykytynViroscience Department, Erasmus Medical Center, 3015 Rotterdam, Netherlands.ORCID 0000-0001-7188-6871
Antonia NetzlCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.ORCID 0000-0001-8034-2382
Simon PollettInfectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Annika RösslerInstitute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Peter-Mayr-Str. 4b, 6020 Innsbruck, Austria.ORCID 0000-0002-5298-0288
Gavin R ScreatonWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.ORCID 0000-0002-3549-4309
Xiaoying ShenDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-8387-3952
Alex SigalAfrica Health Research Institute, Durban 4001, South Africa.ORCID 0000-0001-8571-2004
Viviana SimonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-6416-5096
Rahul SubramanianOffice of Data Science and Emerging Technologies, Office of Science Management and Operations, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-1131-9952
Piyada SupasaWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.ORCID 0009-0006-3931-0569
Mehul S SutharDepartment of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30329, USA.ORCID 0000-0002-2686-8380
Sina TüreliCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.ORCID 0000-0001-7342-9295
Wei WangDivision of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20903, USA.ORCID 0000-0003-2935-6388
Carol D WeissDivision of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20903, USA.ORCID 0000-0002-9965-1289
Derek J SmithCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.ORCID 0000-0002-2393-1890
Funding
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4MTargeting druggable coronavirus proteinsU19AI171443 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SUMIT K CHANDA, Arnab Kumar Chatterjee · 2022 to 2026
$101.4MVACCINE INDUCED IMMUNITY IN THE YOUNG AND AGEDU19AI057266 · NIAID · EMORY UNIVERSITY · PI Rafi Ahmed · 2003 to 2026
$81.7MNIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6MNIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00017 · NIAID · EMORY UNIVERSITY · PI LOWEN, ANICE · 2021 to 2025
$27.3MHuman antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0MGates Foundation INV-018944NIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93021C00014NIAID NIH HHS 75N93021C00017NIAID NIH HHS R01 AI157155NIAID NIH HHS U19 AI057266NIH HHS P51 OD011132Wellcome Trust
Abstract
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires ongoing monitoring to judge the ability of newly arising variants to escape the immune response. A surveillance system necessitates an understanding of differences in neutralization titers measured in different assays and using human and animal serum samples. We compared 18 datasets generated using human, hamster, and mouse serum and six different neutralization assays. Datasets using animal model serum samples showed higher titer magnitudes than datasets using human serum samples in this comparison. Fold change in neutralization of variants compared to ancestral SARS-CoV-2, immunodominance patterns, and antigenic maps were similar among serum samples and assays. Most assays yielded consistent results, except for differences in fold change in cytopathic effect assays. Hamster serum samples were a consistent surrogate for human first-infection serum samples. These results inform the transition of surveillance of SARS-CoV-2 antigenic variation from dependence on human first-infection serum samples to the utilization of serum samples from animal models.
Indexed as
Antibodies, NeutralizingAntibodies, ViralCOVID-19Neutralization TestsSARS-CoV-2AnimalsCricetinaeDisease Models, AnimalHumansMiceAntibodies, NeutralizingAntibodies, Viral
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.